Metraipolis › archive › dc_e45b2d246f04
Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy — Europe PMC PMID:33592060
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/33592060
- DOI
- 10.1371/journal.pone.0247052
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-05T21:30:21.923Z
- SHA-256 of the archived text
cebc0a65d65c9ba5c645436df1fe9918eb447c657e855ecae4d84e8ec7598d41- Stable URL of this page
https://metraipolis.com/documento/dc_e45b2d246f04
How to cite
Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy — Europe PMC PMID:33592060 — Europe PMC (en), https://europepmc.org/article/MED/33592060 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e45b2d246f04 (Metraipolis archive dc_e45b2d246f04, sha256 cebc0a65d65c9ba5c645436df1fe9918eb447c657e855ecae4d84e8ec7598d41)
BibTeX
@misc{dce45b2d246f04,
title = {Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy — Europe PMC PMID:33592060},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/33592060},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e45b2d246f04; sha256 cebc0a65d65c9ba5c645436df1fe9918eb447c657e855ecae4d84e8ec7598d41},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33592060. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Libman-Sacks endocarditis in patients with systemic lupus erythematosus (SLE) is commonly complicated with embolic cerebrovascular disease (CVD) or valve dysfunction for which high-risk valve surgery is frequently performed. However, the role of medical therapy alone for Libman-Sacks endocarditis and associated acute CVD remains undefined. Objective: To determine in this cross-sectional and longitudinal study if conventional anti-inflammatory and anti-thrombotic therapy may be an effective therapy in SLE patients with Libman-Sacks endocarditis and associated acute CVD. Methods and materials: 17 SLE patients with Libman-Sacks endocarditis detected by two-and-three-dimensional transesophageal echocardiography (TEE) and complicated with acute CVD [stroke/TIA, focal brain injury on MRI, or cognitive dysfunction] were treated with conventional anti-inflammatory and anti-thrombotic therapy for a median of 6 months and then underwent repeat TEE, transcranial Doppler, brain MRI, and neurocognitive testing for re-assessment of Libman-Sacks endocarditis and CVD. Results: Valve vegetations decreased in number, diameter, and area (all p ≤0.01); associated valve regurgitation significantly improved (p = 0.04), and valve thickening did not progress (p = 0.56). In 13 (76%) patients, valve vegetations or valve regurgitation resolved or improved in number and size or by ≥1 degree, respectively, as compared to 4 (24%) patients in whom vegetations or valve regurgitation persisted unchanged or increased in size or by ≥1 degree (p = 0.03). Also, cerebromicroembolism, lobar and global gray and white matter cerebral perfusion, ischemic brain lesion load, and neurocognitive dysfunction resolved or significantly improved (all p ≤0.04). Conclusion: These preliminary data suggest that combined conventional anti-inflammatory and antithrombotic therapy may be an effective treatment for Libman-Sacks endocarditis and its associated CVD and may obviate the need for high-risk valve surgery. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-02-16). Identificativi: PMID 33592060 · PMCID PMC7886205 · DOI 10.1371/journal.pone.0247052. Pagina: https://europepmc.org/article/MED/33592060 — https://doi.org/10.1371/journal.pone.0247052. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-05T21:27:29.830Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.